ClinicalTrials.gg
CompletedNCT06215521Updated Feb 24, 2025Results posted

A Study to Evaluate the Effect of Pirtobrutinib (LOXO-305) on QTc Interval in Healthy Participants

A Phase 1 interventional study of Pirtobrutinib and Placebo in Healthy, sponsored by Eli Lilly and Company. Completed at 2 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-24.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Registered 3 years after the study started (first participant enrolled Dec 2020, registered Dec 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The main purpose of this study is to assess the effect of Pirtobrutinib (LOXO-305) on the heart rate-corrected QT (QTc) interval and to conduct blood tests to measure how much pirtobrutinib (LOXO-305) is in the bloodstream and how the body handles and eliminates pirtobrutinib. The study will also evaluate the safety and tolerability of pirtobrutinib. The study will last up to 71 days, including screening.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have (BMI) within the range of 18.0 to 32.0 kilograms per square meter (kg/m²), inclusive at Screening
  • Male and female participants in good health, determined by no findings from medical history, 12-lead (ECG), vital sign measurements, or clinical laboratory evaluations as assessed by the investigator
  • Female participants of non- and male participants who follow standard methods
  • Must have comply with all study procedures, including the 15-night stay at the Clinical Research Unit (CRU) and follow-up phone call

Exclusion criteria

Exclusion Criteria:

  • History or presence of any diseases or conditions of clinical significance by the Investigator (or designee) and/or Sponsor
  • Positive serologic test for surface antigen (HBsAg), hepatitis B virus immunoglobulin M (HBV IgM) core antibody, virus (HCV) antibody, or (HIV) antibody at Screening.
  • Positive polymerase chain reaction (PCR) test for COVID-19 at Screening
  • Known ongoing alcohol and/or drug abuse within 2 years prior to Screening
  • History of significant , intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator (or designee)
  • Have previously received pirtobrutinib (LOXO-305) in any other study investigating pirtobrutinib (LOXO-305), within 30 days prior to Day 1
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Pirtobrutinib

    Pirtobrutinib a single oral dose on Day 1, 12 and 23 following a fast of at least 8 hours prior to and 6 hours after dosing.

    Drug: Pirtobrutinib

  • Placebo comparator
    Placebo

    Placebo (matched to Pirtobrutinib) a single oral dose on Day 1, 12 and 23 following a fast of at least 8 hours prior to and 6 hours after dosing.

    Drug: Placebo

  • Active comparator
    Moxifloxacin

    Moxifloxacin a single oral dose on Day 1, 12 and 23 following a fast of at least 8 hours prior to and 6 hours after dosing.

    Drug: Moxifloxacin

Interventions

  • Administered orally

    Also known as: LOXO-305, LY3527727

  • DrugPlacebo

    Administered orally

  • Administered orally

06

What researchers measure

Primary outcomes

  1. Placebo-corrected Change From Baseline in QT Interval Corrected Using Fridericia's Correction (QTcF) (ΔΔQTcF)

    The cardiodynamic assessment was performed through 12-lead electrocardiogram (ECG) extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. The QT interval is the time from electrocardiogram Q wave to the end of the T wave corresponding to electrical systole. QT interval was corrected for heart rate using QTcF. Placebo-corrected change from baseline in QTcF (ΔΔQTcF) was calculated based on model-predicted effect.

    Time frame: Baseline (Predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12 and 24 hours post-dose

Secondary outcomes

  1. Change From Baseline in (Δ) QTcF

    The cardiodynamic assessment was performed through 12-lead ECG extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. The QT interval is the time from electrocardiogram Q wave to the end of the T wave corresponding to electrical systole. QT interval was corrected for heart rate using QTcF. Change from baseline in (Δ) QTcF was calculated using linear mixed-effects model analysis.

    Time frame: Baseline (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12 and 24 hours post-dose

  2. Change From Baseline in Heart Rate (ΔHR)

    Heart rate is the number of times the ventricles of the heart contract and relax per minute. Change from baseline in heart rate (ΔHR) was calculated using linear mixed-effects model analysis.

    Time frame: Baseline (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12 and 24 hours post-dose

  3. Change From Baseline in Pulse Rate (ΔPR)

    Pulse rate is number of times heart beats per minute. Pulse rate measurements were performed using the same arm for each reading and measurements were taken after the participant had been resting in the supine position for at least 5 minutes. Change from baseline in pulse rate (ΔPR) was calculated using linear mixed-effects model analysis.

    Time frame: Baseline (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12 and 24 hours post-dose

  4. Change From Baseline in QRS Intervals (Δ QRS)

    QRS interval in an ECG measured the total time of ventricular depolarization. It begins with Q or R wave and ends at the end of the S wave. Change from baseline in QRS intervals (Δ QRS) was calculated using linear mixed-effects model analysis.

    Time frame: Baseline (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12 and 24 hours post-dose

  5. Change From Baseline in Individualized Heart Rate-Corrected QT Interval (ΔQTcS), If a Substantial Heart Rate Effect Was Observed

    The cardiodynamic assessment was performed through 12-lead ECG extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. The QT interval is the time from electrocardiogram Q wave to the end of the T wave corresponding to electrical systole. QT interval was corrected for heart rate using QTcS.

    Time frame: Baseline (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12 and 24 hours post-dose

  6. Change From Baseline in Optimized Heart Rate-Corrected QT Interval (ΔQTcI), If a Substantial Heart Rate Effect Was Observed

    The cardiodynamic assessment was performed through 12-lead ECG extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. The QT interval is the time from electrocardiogram Q wave to the end of the T wave corresponding to electrical systole. QT interval was corrected for heart rate using QTcI.

    Time frame: Baseline (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12 and 24 hours post-dose

  7. Placebo-corrected Change From Baseline in Heart Rate (ΔΔHR)

    Heart rate is the number of times the ventricles of the heart contract and relax per minute. Placebo-corrected change from baseline in heart rate (ΔΔHR) was calculated using linear mixed-effects model analysis.

    Time frame: Baseline (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12 and 24 hours post-dose

  8. Placebo-corrected Change From Baseline in Pulse Rate (ΔΔ PR)

    Pulse rate is number of times heart beats per minute. Pulse rate measurements were performed using the same arm for each reading and measurements were taken after the participant had been resting in the supine position for at least 5 minutes. Placebo-corrected change from baseline in pulse rate (ΔPR) was calculated using linear mixed-effects model analysis.

    Time frame: Baseline (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12 and 24 hours post-dose

  9. Placebo-Corrected Change From Baseline in QRS (ΔΔQRS)

    QRS interval in an ECG measured the total time of ventricular depolarization. It begins with Q or R wave and ends at the end of the S wave. Placebo-corrected change from baseline in QRS intervals (ΔΔQRS) was calculated using linear mixed-effects model analysis.

    Time frame: Baseline (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12 and 24 hours post-dose

  10. Placebo-corrected Change From Baseline in ΔQTcF (ΔΔQTcF), If a Substantial Heart Rate Effect Was Observed

    The cardiodynamic assessment was performed through 12-lead ECG extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. The QT interval is the time from electrocardiogram Q wave to the end of the T wave corresponding to electrical systole. QT interval was corrected for heart rate using QTcF.

    Time frame: Baseline (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12 and 24 hours post-dose

  11. Placebo-corrected Change From Baseline in Individualized Heart Rate-Corrected QT Interval (ΔΔQTcS), If a Substantial Heart Rate Effect Was Observed

    The cardiodynamic assessment was performed through 12-lead ECG extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. The QT interval is the time from electrocardiogram Q wave to the end of the T wave corresponding to electrical systole. QT interval was corrected for heart rate using QTcS.

    Time frame: Baseline (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12 and 24 hours post-dose

  12. Placebo-corrected Change From Baseline in Optimized Heart Rate-Corrected QT Interval (ΔΔQTcI), If a Substantial Heart Rate Effect Was Observed

    The cardiodynamic assessment was performed through 12-lead ECG extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. The QT interval is the time from electrocardiogram Q wave to the end of the T wave corresponding to electrical systole. QT interval was corrected for heart rate using QTcI.

    Time frame: Baseline (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12 and 24 hours post-dose

  13. Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Changes

    The cardiodynamic assessment was performed through 12-lead ECG extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. Number of participants with potentially clinically significant ECG changes were reported.

    Time frame: Baseline up to Day 33

  14. Number of Participants With Treatment Emergent Changes in T-wave Morphology and U-wave Presence

    The cardiodynamic assessment was performed through 12-lead ECG extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. Number of participants with treatment emergent changes in T-wave morphology and U-wave presence were reported.

    Time frame: Baseline up to Day 33

  15. Pharmacokinetic (PK): Percentage of AUC0-inf Extrapolated (AUC%Extrap) of Pirtobrutinib

    PK: %AUCextrap was defined as percentage extrapolation for AUC0-inf.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12, 24, 48, 72, and 96 hours post-dose

  16. PK: Mean Residence Time (MRT) of Pirtobrutinib

    PK: MRT was calculated by the area under the first moment curve divided by the area under the concentration time curve.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12, 24, 48, 72, and 96 hours post-dose

  17. PK: Apparent Volume of Distribution at the Terminal Phase (Vz/F) of Pirtobrutinib

    PK: Vz/F was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vz/F was calculated as (CL/F)/Lambda Z. Where, CL/F is the apparent total clearance and lambda Z is the apparent terminal elimination rate constant.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12, 24, 48, 72, and 96 hours post-dose

  18. PK: Time to Maximum Observed Plasma Concentration (Tmax) of Pirtobrutinib

    PK: Tmax was defined as the time to reach maximum observed plasma concentration (Cmax) for pirtobrutinib.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12, 24, 48, 72, and 96 hours post-dose

  19. PK: Apparent Plasma Terminal Elimination Half-life (t1/2) of Pirtobrutinib

    PK: t1/2 was defined as the terminal elimination phase half-life for pirtobrutinib.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12, 24, 48, 72, and 96 hours post-dose

  20. PK: Maximum Observed Concentration (Cmax) of Pirtobrutinib

    PK: Cmax was defined as the maximum plasma concentration for pirtobrutinib.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12, 24, 48, 72, and 96 hours post-dose

  21. PK: Area Under the Concentration-time Curve, From Time 0 to 24 Hours Post-dose (AUC0-24) of Pirtobrutinib

    PK: AUC(0-24) was defined as the area under the plasma concentration-time curve from 0 time to 24 hours post-dose.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12, 24 hours post-dose

  22. PK: Area Under the Concentration-time Curve, From Time 0 to the Last Measurable Concentration (AUC0-t) of Pirtobrutinib

    PK: AUC(0-t) was defined as the area under the plasma concentration-time curve from 0 time to last measurable point for pirtobrutinib.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12, 24, 48, 72, and 96 hours post-dose

  23. PK: Apparent Systemic Clearance (CL/F) of Pirtobrutinib

    PK: Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as (Dose/AUC(0-inf))/F. Where AUC(0-inf) is the area under the plasma concentration-time curve from zero to infinity and F is the bioavailability of the drug.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12, 24, 48, 72, and 96 hours post-dose

  24. PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Pirtobrutinib

    PK: AUC(0-inf) was defined as the area under the plasma concentration-time curve from 0 to infinity for pirtobrutinib.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12, 24, 48, 72, and 96 hours post-dose

  25. PK: Apparent Terminal Elimination Rate Constant (λZ) of Pirtobrutinib

    PK: Terminal elimination rate constant, calculated as the negative of the slope of the log-linear regression of the natural logarithm concentration-time curve during the terminal phase.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12, 24, 48, 72, and 96 hours post-dose

07

Results

Posted Feb 24, 2025

Participant flow

Treatment Period 1 (Day 1)
Participant flow — Treatment Period 1 (Day 1)
MilestoneTreatment Sequence 1: ABCTreatment Sequence 2: BCATreatment Sequence 3: CABTreatment Sequence 4: ACBTreatment Sequence 5: CBATreatment Sequence 6: BAC
Started565555
Received 1 dose of treatment a555555
Received 1 dose of treatment b565555
Received 1 dose of treatment c555555
Completed555555
Not completed010000
Withdrew: Adverse event010000
Treatment Period 2 (Day 12)
Participant flow — Treatment Period 2 (Day 12)
MilestoneTreatment Sequence 1: ABCTreatment Sequence 2: BCATreatment Sequence 3: CABTreatment Sequence 4: ACBTreatment Sequence 5: CBATreatment Sequence 6: BAC
Started555555
Completed555555
Not completed000000
Treatment Period 3 (Day 23)
Participant flow — Treatment Period 3 (Day 23)
MilestoneTreatment Sequence 1: ABCTreatment Sequence 2: BCATreatment Sequence 3: CABTreatment Sequence 4: ACBTreatment Sequence 5: CBATreatment Sequence 6: BAC
Started555555
Completed555555
Not completed000000

Outcome measures

PrimaryPlacebo-corrected Change From Baseline in QT Interval Corrected Using Fridericia's Correction (QTcF) (ΔΔQTcF)

The cardiodynamic assessment was performed through 12-lead electrocardiogram (ECG) extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. The QT interval is the time from electrocardiogram Q wave to the end of the T wave corresponding to electrical systole. QT interval was corrected for heart rate using QTcF. Placebo-corrected change from baseline in QTcF (ΔΔQTcF) was calculated based on model-predicted effect.

Time frame:
Baseline (Predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12 and 24 hours post-dose
Reported as:
Least squares mean · milliseconds (msec)
Placebo-corrected Change From Baseline in QT Interval Corrected Using Fridericia's Correction (QTcF) (ΔΔQTcF)
milliseconds (msec)Treatment A: 900 mg Pirtobrutinib
Placebo-corrected Change From Baseline in QT Interval Corrected Using Fridericia's Correction (QTcF) (ΔΔQTcF)0.73 (-1.17 to 2.64)
SecondaryChange From Baseline in (Δ) QTcF

The cardiodynamic assessment was performed through 12-lead ECG extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. The QT interval is the time from electrocardiogram Q wave to the end of the T wave corresponding to electrical systole. QT interval was corrected for heart rate using QTcF. Change from baseline in (Δ) QTcF was calculated using linear mixed-effects model analysis.

Time frame:
Baseline (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12 and 24 hours post-dose
Reported as:
Least squares mean · msec
Change From Baseline in (Δ) QTcF
msecTreatment A: 900 mg PirtobrutinibTreatment B: 900 mg Pirtobrutinib Matched PlaceboTreatment C: 400 mg Moxifloxacin
Change at 0.25 hour post-dose-0.4 (-1.41 to 0.68)0.0 (-1.01 to 1.08)-0.1 (-1.15 to 0.97)
Change at 0.5 hour post-dose-4.5 (-5.94 to -3.06)-2.8 (-4.21 to -1.33)4.2 (2.72 to 5.66)
Change at 0.75 hour post-dose-3.8 (-5.37 to -2.29)-2.0 (-3.50 to -0.42)7.6 (6.03 to 9.17)
Change at 1 hour post-dose-2.8 (-4.25 to -1.33)-1.2 (-2.65 to 0.24)8.3 (6.88 to 9.80)
Change at 1.5 hours post-dose-0.6 (-2.26 to 0.98)-1.0 (-2.63 to 0.61)9.8 (8.15 to 11.45)
Change at 2 hours post-dose-2.2 (-3.89 to -0.49)-1.1 (-2.80 to 0.60)9.4 (7.64 to 11.10)
Change at 2.5 hours post-dose-0.2 (-1.89 to 1.46)0.2 (-1.45 to 1.90)10.1 (8.39 to 11.82)
Change at 3 hours post-dose0.3 (-1.45 to 2.13)0.5 (-1.26 to 2.32)9.9 (8.11 to 11.75)
Change at 4 hours post-dose2.2 (0.18 to 4.19)0.3 (-1.70 to 2.32)9.8 (7.78 to 11.86)
Change at 6 hours post-dose3.5 (1.48 to 5.42)0.9 (-1.08 to 2.86)9.3 (7.26 to 11.26)
Change at 8.5 hours post-dose-5.1 (-7.07 to -3.09)-5.2 (-7.15 to -3.17)2.8 (0.80 to 4.85)
Change at 12 hours post-dose1.2 (-1.41 to 3.75)0.6 (-1.99 to 3.17)6.8 (4.12 to 9.44)
Change at 24 hours post-dose0.0 (-1.71 to 1.69)0.6 (-1.11 to 2.41)5.0 (3.22 to 6.74)
SecondaryChange From Baseline in Heart Rate (ΔHR)

Heart rate is the number of times the ventricles of the heart contract and relax per minute. Change from baseline in heart rate (ΔHR) was calculated using linear mixed-effects model analysis.

Time frame:
Baseline (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12 and 24 hours post-dose
Reported as:
Least squares mean · beats per minute (beats/min)
Change From Baseline in Heart Rate (ΔHR)
beats per minute (beats/min)Treatment A: 900 mg PirtobrutinibTreatment B: 900 mg Pirtobrutinib Matched Placebo
Change at 0.25 hour post-dose0.1 (-0.94 to 1.07)-0.9 (-1.81 to 0.09)
Change at 0.5 hour post-dose-0.5 (-1.66 to 0.61)-1.2 (-2.24 to -0.07)
Change at 0.75 hour post-dose0.0 (-1.28 to 1.23)-0.4 (-1.66 to 0.76)
Change at 1 hour post-dose1.0 (-0.23 to 2.32)-0.1 (-1.34 to 1.09)
Change at 1.5 hours post-dose0.9 (-0.28 to 2.06)-1.7 (-2.82 to -0.58)
Change at 2 hours post-dose0.5 (-0.73 to 1.76)-0.8 (-1.98 to 0.42)
Change at 2.5 hours post-dose2.2 (0.87 to 3.54)-0.1 (-1.37 to 1.22)
Change at 3 hours post-dose1.3 (-0.01 to 2.52)0.4 (-0.84 to 1.60)
Change at 4 hours post-dose1.4 (0.12 to 2.67)0.4 (-0.85 to 1.61)
Change at 6 hours post-dose2.0 (0.65 to 3.43)0.5 (-0.88 to 1.82)
Change at 8.5 hours post-dose4.0 (2.42 to 5.59)3.4 (1.89 to 5.00)
Change at 12 hours post-dose2.0 (0.22 to 3.74)0.4 (-1.36 to 2.09)
Change at 24 hours post-dose1.2 (0.00 to 2.48)0.8 (-0.41 to 2.04)
SecondaryChange From Baseline in Pulse Rate (ΔPR)

Pulse rate is number of times heart beats per minute. Pulse rate measurements were performed using the same arm for each reading and measurements were taken after the participant had been resting in the supine position for at least 5 minutes. Change from baseline in pulse rate (ΔPR) was calculated using linear mixed-effects model analysis.

Time frame:
Baseline (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12 and 24 hours post-dose
Reported as:
Least squares mean · beats per minute (beats/min)
Change From Baseline in Pulse Rate (ΔPR)
beats per minute (beats/min)Treatment A: 900 mg PirtobrutinibTreatment B: 900 mg Pirtobrutinib Matched Placebo
Change at 0.25 hour post-dose-2.6 (-4.46 to -0.83)-0.8 (-2.60 to 1.02)
Change at 0.5 hour post-dose0.3 (-1.61 to 2.15)1.5 (-0.42 to 3.34)
Change at 0.75 hour post-dose0.3 (-1.41 to 1.98)1.0 (-0.72 to 2.67)
Change at 1 hour post-dose-0.1 (-2.24 to 2.11)0.7 (-1.48 to 2.83)
Change at 1.5 hours post-dose-0.9 (-2.69 to 0.81)-1.2 (-2.96 to 0.54)
Change at 2 hours post-dose-0.5 (-1.97 to 0.99)-0.5 (-1.94 to 1.01)
Change at 2.5 hours post-dose-3.9 (-5.82 to -2.02)-0.8 (-2.73 to 1.06)
Change at 3 hours post-dose-0.9 (-2.87 to 1.13)-1.3 (-3.30 to 0.70)
Change at 4 hours post-dose-1.6 (-3.23 to 0.05)-2.3 (-3.91 to -0.64)
Change at 6 hours post-dose-4.4 (-6.12 to -2.73)-2.7 (-4.34 to -0.96)
Change at 8.5 hours post-dose-6.2 (-8.30 to -4.06)-5.1 (-7.24 to -3.00)
Change at 12 hours post-dose-4.9 (-7.82 to -1.88)-2.8 (-5.77 to 0.17)
Change at 24 hours post-dose-4.2 (-6.59 to -1.75)-0.6 (-3.11 to 1.90)
SecondaryChange From Baseline in QRS Intervals (Δ QRS)

QRS interval in an ECG measured the total time of ventricular depolarization. It begins with Q or R wave and ends at the end of the S wave. Change from baseline in QRS intervals (Δ QRS) was calculated using linear mixed-effects model analysis.

Time frame:
Baseline (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12 and 24 hours post-dose
Reported as:
Least squares mean · msec
Change From Baseline in QRS Intervals (Δ QRS)
msecTreatment A: 900 mg PirtobrutinibTreatment B: Pirtobrutinib Matched Placebo
Change at 0.25 hour post-dose0.0 (-0.24 to 0.24)0.0 (-0.26 to 0.22)
Change at 0.5 hour post-dose0.2 (-0.03 to 0.45)-0.1 (-0.37 to 0.11)
Change at 0.75 hour post-dose0.2 (-0.01 to 0.42)0.0 (-0.18 to 0.25)
Change at 1 hour post-dose0.2 (-0.18 to 0.49)-0.1 (-0.43 to 0.22)
Change at 1.5 hours post-dose-0.1 (-0.34 to 0.17)-0.1 (-0.35 to 0.15)
Change at 2 hours post-dose0.0 (-0.29 to 0.20)-0.1 (-0.33 to 0.16)
Change at 2.5 hours post-dose-0.1 (-0.39 to 0.18)-0.1 (-0.41 to 0.15)
Change at 3 hours post-dose0.2 (-0.06 to 0.50)-0.1 (-0.38 to 0.18)
Change at 4 hours post-dose0.2 (-0.13 to 0.44)0.1 (-0.19 to 0.37)
Change at 6 hours post-dose0.7 (0.30 to 1.01)0.2 (-0.19 to 0.52)
Change at 8.5 hours post-dose-0.6 (-1.17 to -0.12)0.1 (-0.42 to 0.63)
Change at 12 hours post-dose0.4 (-0.11 to 0.83)0.3 (-0.16 to 0.78)
Change at 24 hours post-dose0.2 (-0.81 to 1.23)-1.0 (-2.03 to 0.10)
SecondaryChange From Baseline in Individualized Heart Rate-Corrected QT Interval (ΔQTcS), If a Substantial Heart Rate Effect Was Observed

The cardiodynamic assessment was performed through 12-lead ECG extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. The QT interval is the time from electrocardiogram Q wave to the end of the T wave corresponding to electrical systole. QT interval was corrected for heart rate using QTcS.

Time frame:
Baseline (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12 and 24 hours post-dose
Reported as:
Least squares mean · msec
Change From Baseline in Individualized Heart Rate-Corrected QT Interval (ΔQTcS), If a Substantial Heart Rate Effect Was Observed
msecTreatment A: 900 mg PirtobrutinibTreatment B: Pirtobrutinib Matched Placebo
Change From Baseline in Individualized Heart Rate-Corrected QT Interval (ΔQTcS), If a Substantial Heart Rate Effect Was ObservedNA (NA to NA)NA (NA to NA)
SecondaryChange From Baseline in Optimized Heart Rate-Corrected QT Interval (ΔQTcI), If a Substantial Heart Rate Effect Was Observed

The cardiodynamic assessment was performed through 12-lead ECG extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. The QT interval is the time from electrocardiogram Q wave to the end of the T wave corresponding to electrical systole. QT interval was corrected for heart rate using QTcI.

Time frame:
Baseline (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12 and 24 hours post-dose
Reported as:
Least squares mean · msec
Change From Baseline in Optimized Heart Rate-Corrected QT Interval (ΔQTcI), If a Substantial Heart Rate Effect Was Observed
msecTreatment A: 900 mg PirtobrutinibTreatment B: Pirtobrutinib Matched Placebo
Change From Baseline in Optimized Heart Rate-Corrected QT Interval (ΔQTcI), If a Substantial Heart Rate Effect Was ObservedNA (NA to NA)NA (NA to NA)
SecondaryPlacebo-corrected Change From Baseline in Heart Rate (ΔΔHR)

Heart rate is the number of times the ventricles of the heart contract and relax per minute. Placebo-corrected change from baseline in heart rate (ΔΔHR) was calculated using linear mixed-effects model analysis.

Time frame:
Baseline (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12 and 24 hours post-dose
Reported as:
Least squares mean · beats/min
Placebo-corrected Change From Baseline in Heart Rate (ΔΔHR)
beats/minTreatment A: 900 mg PirtobrutinibTreatment C: 400 mg Moxifloxacin
Change at 0.25 hours post-dose0.9 (-0.11 to 1.96)0.1 (-0.92 to 1.15)
Change at 0.5 hours post-dose0.6 (-0.65 to 1.90)3.0 (1.71 to 4.27)
Change at 0.75 hours post-dose0.4 (-1.06 to 1.91)3.8 (2.35 to 5.34)
Change at 1 hour post-dose1.2 (-0.33 to 2.68)4.2 (2.71 to 5.71)
Change at 1.5 hours post-dose2.6 (1.26 to 3.92)2.8 (1.43 to 4.10)
Change at 2 hours post-dose1.3 (-0.18 to 2.77)2.5 (1.02 to 3.99)
Change at 2.5 hours post-dose2.3 (0.66 to 3.90)2.9 (1.25 to 4.53)
Change at 3 hours post-dose0.9 (-0.63 to 2.38)1.1 (-0.38 to 2.65)
Change at 4 hours post-dose1.0 (-0.51 to 2.53)1.9 (0.34 to 3.40)
Change at 6 hours post-dose1.6 (-0.14 to 3.28)2.6 (0.86 to 4.32)
Change at 8.5 hours post-dose0.6 (-1.47 to 2.58)1.5 (-0.54 to 3.54)
Change at 12 hours post-dose1.6 (-0.68 to 3.91)4.5 (2.16 to 6.82)
Change at 24 hours post-dose0.4 (-1.06 to 1.91)1.0 (-0.47 to 2.54)
SecondaryPlacebo-corrected Change From Baseline in Pulse Rate (ΔΔ PR)

Pulse rate is number of times heart beats per minute. Pulse rate measurements were performed using the same arm for each reading and measurements were taken after the participant had been resting in the supine position for at least 5 minutes. Placebo-corrected change from baseline in pulse rate (ΔPR) was calculated using linear mixed-effects model analysis.

Time frame:
Baseline (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12 and 24 hours post-dose
Reported as:
Least squares mean · beats/min
Placebo-corrected Change From Baseline in Pulse Rate (ΔΔ PR)
beats/minTreatment A: 900 mg PirtobrutinibTreatment C: 400 mg Moxifloxacin
Change at 0.25 hours post-dose-1.9 (-4.28 to 0.56)-1.2 (-3.65 to 1.24)
Change at 0.5 hours post-dose-1.2 (-3.72 to 1.33)-2.1 (-4.68 to 0.42)
Change at 0.75 hours post-dose-0.7 (-2.93 to 1.55)-2.5 (-4.80 to -0.27)
Change at 1 hours post-dose-0.7 (-3.69 to 2.20)-3.8 (-6.78 to -0.88)
Change at 1.5 hours post-dose0.3 (-2.05 to 2.60)-3.4 (-5.78 to -1.09)
Change at 2 hours post-dose0.0 (-1.94 to 1.89)-3.6 (-5.54 to -1.68)
Change at 2.5 hours post-dose-3.1 (-5.64 to -0.54)-4.6 (-7.23 to -2.05)
Change at 3 hours post-dose0.4 (-2.27 to 3.13)-4.0 (-6.70 to -1.26)
Change at 4 hours post-dose0.7 (-1.47 to 2.85)-4.2 (-6.33 to -1.98)
Change at 6 hours post-dose-1.8 (-4.01 to 0.47)-4.3 (-6.53 to -2.02)
Change at 8.5 hours post-dose-1.1 (-3.94 to 1.82)-2.1 (-5.00 to 0.80)
Change at 12 hours post-dose-2.1 (-6.17 to 2.06)-3.5 (-7.63 to 0.71)
Change at 24 hours post-dose-3.6 (-6.95 to -0.18)-0.8 (-4.19 to 2.69)
SecondaryPlacebo-Corrected Change From Baseline in QRS (ΔΔQRS)

QRS interval in an ECG measured the total time of ventricular depolarization. It begins with Q or R wave and ends at the end of the S wave. Placebo-corrected change from baseline in QRS intervals (ΔΔQRS) was calculated using linear mixed-effects model analysis.

Time frame:
Baseline (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12 and 24 hours post-dose
Reported as:
Least squares mean · msec
Placebo-Corrected Change From Baseline in QRS (ΔΔQRS)
msecTreatment A: 900 mg PirtobrutinibTreatment C: 400 mg Moxifloxacin
Change at 0.25 hours post-dose0.0 (-0.32 to 0.36)-0.3 (-0.63 to 0.06)
Change at 0.5 hours post-dose0.3 (0.00 to 0.68)0.1 (-0.26 to 0.43)
Change at 0.75 hours post-dose0.2 (-0.13 to 0.47)0.3 (0.03 to 0.63)
Change at 1 hours post-dose0.3 (-0.21 to 0.73)0.1 (-0.34 to 0.59)
Change at 1.5 hours post-dose0.0 (-0.34 to 0.37)0.1 (-0.22 to 0.49)
Change at 2 hours post-dose0.0 (-0.30 to 0.39)0.1 (-0.20 to 0.50)
Change at 2.5 hours post-dose0.0 (-0.37 to 0.43)0.1 (-0.33 to 0.48)
Change at 3 hours post-dose0.3 (-0.07 to 0.72)-0.1 (-0.50 to 0.29)
Change at 4 hours post-dose0.1 (-0.33 to 0.46)-0.3 (-0.67 to 0.13)
Change at 6 hours post-dose0.5 (-0.01 to 0.99)-0.1 (-0.58 to 0.43)
Change at 8.5 hours post-dose-0.8 (-1.50 to -0.01)-0.4 (-1.12 to 0.38)
Change at 12 hours post-dose0.1 (-0.62 to 0.72)0.0 (-0.65 to 0.70)
Change at 24 hours post-dose1.2 (-0.30 to 2.65)0.2 (-1.25 to 1.74)
SecondaryPlacebo-corrected Change From Baseline in ΔQTcF (ΔΔQTcF), If a Substantial Heart Rate Effect Was Observed

The cardiodynamic assessment was performed through 12-lead ECG extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. The QT interval is the time from electrocardiogram Q wave to the end of the T wave corresponding to electrical systole. QT interval was corrected for heart rate using QTcF.

Time frame:
Baseline (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12 and 24 hours post-dose
Reported as:
Least squares mean · msec
Placebo-corrected Change From Baseline in ΔQTcF (ΔΔQTcF), If a Substantial Heart Rate Effect Was Observed
msecTreatment A: 900 mg PirtobrutinibTreatment B: 900 mg Pirtobrutinib Matched Placebo
Placebo-corrected Change From Baseline in ΔQTcF (ΔΔQTcF), If a Substantial Heart Rate Effect Was ObservedNA (NA to NA)NA (NA to NA)
SecondaryPlacebo-corrected Change From Baseline in Individualized Heart Rate-Corrected QT Interval (ΔΔQTcS), If a Substantial Heart Rate Effect Was Observed

The cardiodynamic assessment was performed through 12-lead ECG extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. The QT interval is the time from electrocardiogram Q wave to the end of the T wave corresponding to electrical systole. QT interval was corrected for heart rate using QTcS.

Time frame:
Baseline (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12 and 24 hours post-dose
Reported as:
Least squares mean · msec
Placebo-corrected Change From Baseline in Individualized Heart Rate-Corrected QT Interval (ΔΔQTcS), If a Substantial Heart Rate Effect Was Observed
msecTreatment A: 900 mg PirtobrutinibTreatment B: 900 mg Pirtobrutinib Matched Placebo
Placebo-corrected Change From Baseline in Individualized Heart Rate-Corrected QT Interval (ΔΔQTcS), If a Substantial Heart Rate Effect Was ObservedNA (NA to NA)NA (NA to NA)
SecondaryPlacebo-corrected Change From Baseline in Optimized Heart Rate-Corrected QT Interval (ΔΔQTcI), If a Substantial Heart Rate Effect Was Observed

The cardiodynamic assessment was performed through 12-lead ECG extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. The QT interval is the time from electrocardiogram Q wave to the end of the T wave corresponding to electrical systole. QT interval was corrected for heart rate using QTcI.

Time frame:
Baseline (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12 and 24 hours post-dose
Reported as:
Least squares mean · msec
Placebo-corrected Change From Baseline in Optimized Heart Rate-Corrected QT Interval (ΔΔQTcI), If a Substantial Heart Rate Effect Was Observed
msecTreatment A: 900 mg PirtobrutinibTreatment B: 900 mg Pirtobrutinib Matched Placebo
Placebo-corrected Change From Baseline in Optimized Heart Rate-Corrected QT Interval (ΔΔQTcI), If a Substantial Heart Rate Effect Was ObservedNA (NA to NA)NA (NA to NA)
SecondaryNumber of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Changes

The cardiodynamic assessment was performed through 12-lead ECG extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. Number of participants with potentially clinically significant ECG changes were reported.

Time frame:
Baseline up to Day 33
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Changes
ParticipantsTreatment A: 900 mg PirtobrutinibTreatment B: 900 mg Pirtobrutinib Matched Placebo
Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Changes00
SecondaryNumber of Participants With Treatment Emergent Changes in T-wave Morphology and U-wave Presence

The cardiodynamic assessment was performed through 12-lead ECG extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. Number of participants with treatment emergent changes in T-wave morphology and U-wave presence were reported.

Time frame:
Baseline up to Day 33
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Changes in T-wave Morphology and U-wave Presence
ParticipantsTreatment A: 900 mg PirtobrutinibTreatment B: 900 mg Pirtobrutinib Matched Placebo
Treatment Emergent Changes in T-wave Morphology00
Treatment Emergent Changes in U-wave Presence00
SecondaryPharmacokinetic (PK): Percentage of AUC0-inf Extrapolated (AUC%Extrap) of Pirtobrutinib

PK: %AUCextrap was defined as percentage extrapolation for AUC0-inf.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12, 24, 48, 72, and 96 hours post-dose
Reported as:
Geometric mean · percentage of AUC
Pharmacokinetic (PK): Percentage of AUC0-inf Extrapolated (AUC%Extrap) of Pirtobrutinib
percentage of AUCTreatment A: 900 mg Pirtobrutinib
Pharmacokinetic (PK): Percentage of AUC0-inf Extrapolated (AUC%Extrap) of Pirtobrutinib5.41 ± 42.0
SecondaryPK: Mean Residence Time (MRT) of Pirtobrutinib

PK: MRT was calculated by the area under the first moment curve divided by the area under the concentration time curve.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12, 24, 48, 72, and 96 hours post-dose
Reported as:
Geometric mean · hours
PK: Mean Residence Time (MRT) of Pirtobrutinib
hoursTreatment A: 900 mg Pirtobrutinib
PK: Mean Residence Time (MRT) of Pirtobrutinib33.6 ± 14.6
SecondaryPK: Apparent Volume of Distribution at the Terminal Phase (Vz/F) of Pirtobrutinib

PK: Vz/F was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vz/F was calculated as (CL/F)/Lambda Z. Where, CL/F is the apparent total clearance and lambda Z is the apparent terminal elimination rate constant.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12, 24, 48, 72, and 96 hours post-dose
Reported as:
Geometric mean · liter
PK: Apparent Volume of Distribution at the Terminal Phase (Vz/F) of Pirtobrutinib
literTreatment A: 900 mg Pirtobrutinib
PK: Apparent Volume of Distribution at the Terminal Phase (Vz/F) of Pirtobrutinib62.1 ± 22.5
SecondaryPK: Time to Maximum Observed Plasma Concentration (Tmax) of Pirtobrutinib

PK: Tmax was defined as the time to reach maximum observed plasma concentration (Cmax) for pirtobrutinib.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12, 24, 48, 72, and 96 hours post-dose
Reported as:
Median · hours
PK: Time to Maximum Observed Plasma Concentration (Tmax) of Pirtobrutinib
hoursTreatment A: 900 mg Pirtobrutinib
PK: Time to Maximum Observed Plasma Concentration (Tmax) of Pirtobrutinib4.01 (3.00 to 24.0)
SecondaryPK: Apparent Plasma Terminal Elimination Half-life (t1/2) of Pirtobrutinib

PK: t1/2 was defined as the terminal elimination phase half-life for pirtobrutinib.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12, 24, 48, 72, and 96 hours post-dose
Reported as:
Geometric mean · hours
PK: Apparent Plasma Terminal Elimination Half-life (t1/2) of Pirtobrutinib
hoursTreatment A: 900 mg Pirtobrutinib
PK: Apparent Plasma Terminal Elimination Half-life (t1/2) of Pirtobrutinib23.0 ± 14.5
SecondaryPK: Maximum Observed Concentration (Cmax) of Pirtobrutinib

PK: Cmax was defined as the maximum plasma concentration for pirtobrutinib.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12, 24, 48, 72, and 96 hours post-dose
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
PK: Maximum Observed Concentration (Cmax) of Pirtobrutinib
nanogram per milliliter (ng/mL)Treatment A: 900 mg Pirtobrutinib
PK: Maximum Observed Concentration (Cmax) of Pirtobrutinib14300 ± 23.1
SecondaryPK: Area Under the Concentration-time Curve, From Time 0 to 24 Hours Post-dose (AUC0-24) of Pirtobrutinib

PK: AUC(0-24) was defined as the area under the plasma concentration-time curve from 0 time to 24 hours post-dose.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12, 24 hours post-dose
Reported as:
Geometric mean · hour*nanogram per milliliter (h*ng/mL)
PK: Area Under the Concentration-time Curve, From Time 0 to 24 Hours Post-dose (AUC0-24) of Pirtobrutinib
hour*nanogram per milliliter (h*ng/mL)Treatment A: 900 mg Pirtobrutinib
PK: Area Under the Concentration-time Curve, From Time 0 to 24 Hours Post-dose (AUC0-24) of Pirtobrutinib229000 ± 17.5
SecondaryPK: Area Under the Concentration-time Curve, From Time 0 to the Last Measurable Concentration (AUC0-t) of Pirtobrutinib

PK: AUC(0-t) was defined as the area under the plasma concentration-time curve from 0 time to last measurable point for pirtobrutinib.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12, 24, 48, 72, and 96 hours post-dose
Reported as:
Geometric mean · h*ng/mL
PK: Area Under the Concentration-time Curve, From Time 0 to the Last Measurable Concentration (AUC0-t) of Pirtobrutinib
h*ng/mLTreatment A: 900 mg Pirtobrutinib
PK: Area Under the Concentration-time Curve, From Time 0 to the Last Measurable Concentration (AUC0-t) of Pirtobrutinib452000 ± 20.7
SecondaryPK: Apparent Systemic Clearance (CL/F) of Pirtobrutinib

PK: Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as (Dose/AUC(0-inf))/F. Where AUC(0-inf) is the area under the plasma concentration-time curve from zero to infinity and F is the bioavailability of the drug.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12, 24, 48, 72, and 96 hours post-dose
Reported as:
Geometric mean · liter per hour (L/h)
PK: Apparent Systemic Clearance (CL/F) of Pirtobrutinib
liter per hour (L/h)Treatment A: 900 mg Pirtobrutinib
PK: Apparent Systemic Clearance (CL/F) of Pirtobrutinib1.88 ± 21.4
SecondaryPK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Pirtobrutinib

PK: AUC(0-inf) was defined as the area under the plasma concentration-time curve from 0 to infinity for pirtobrutinib.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12, 24, 48, 72, and 96 hours post-dose
Reported as:
Geometric mean · h*ng/mL
PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Pirtobrutinib
h*ng/mLTreatment A: 900 mg Pirtobrutinib
PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Pirtobrutinib480000 ± 21.4
SecondaryPK: Apparent Terminal Elimination Rate Constant (λZ) of Pirtobrutinib

PK: Terminal elimination rate constant, calculated as the negative of the slope of the log-linear regression of the natural logarithm concentration-time curve during the terminal phase.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12, 24, 48, 72, and 96 hours post-dose
Reported as:
Number · one per hour (1/h)
PK: Apparent Terminal Elimination Rate Constant (λZ) of Pirtobrutinib
one per hour (1/h)Treatment A: 900 mg Pirtobrutinib
Participant 10.0320
Participant 20.0270
Participant 30.0356
Participant 40.0259
Participant 50.0270
Participant 60.0330
Participant 70.0310
Participant 80.0331
Participant 90.0353
Participant 100.0322
Participant 110.0271
Participant 120.0213
Participant 130.0337
Participant 140.0273
Participant 150.0229
Participant 160.0314
Participant 170.0364
Participant 180.0289
Participant 190.0309
Participant 200.0271
Participant 210.0269
Participant 220.0422
Participant 230.0346
Participant 240.0273
Participant 250.0288
Participant 260.0306
Participant 270.0364
Participant 280.0299
Participant 290.0304
Participant 300.0283

Adverse events

Collected over Baseline up to follow-up (up to Day 42). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment A: 900 mg Pirtobrutinib0/30 (0%)0/30 (0%)6/30 (20%)
Treatment B: 900 mg Pirtobrutinib Matched Placebo0/31 (0%)0/31 (0%)1/31 (3.2%)
Treatment C: 400 mg Moxifloxacin0/30 (0%)0/30 (0%)1/30 (3.3%)
Most frequent other events
Most frequent other events
EventTreatment A: 900 mg PirtobrutinibTreatment B: 900 mg Pirtobrutinib Matched PlaceboTreatment C: 400 mg Moxifloxacin
HeadacheNervous system disorders5/301/311/30
DiarrhoeaGastrointestinal disorders2/300/310/30

Baseline characteristics

All participants who received 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Treatment Sequence: ABCTreatment Sequence: BCATreatment Sequence: CABTreatment Sequence: ACBTreatment Sequence: CBATreatment Sequence: BACTotal
Mean35.0 ± 9.8739.0 ± 8.8137.8 ± 7.9535.6 ± 7.8634.4 ± 6.7738.2 ± 10.0136.7 ± 8.08
Sex: Female, Male
Sex: Female, Male(Participants)Treatment Sequence: ABCTreatment Sequence: BCATreatment Sequence: CABTreatment Sequence: ACBTreatment Sequence: CBATreatment Sequence: BACTotal
Female1220027
Male44355324
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment Sequence: ABCTreatment Sequence: BCATreatment Sequence: CABTreatment Sequence: ACBTreatment Sequence: CBATreatment Sequence: BACTotal
Hispanic or Latino1012138
Not Hispanic or Latino46434223
Unknown or Not Reported0000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment Sequence: ABCTreatment Sequence: BCATreatment Sequence: CABTreatment Sequence: ACBTreatment Sequence: CBATreatment Sequence: BACTotal
American Indian or Alaska Native0001001
Asian1000001
Native Hawaiian or Other Pacific Islander0000101
Black or African American44211214
White02333314
More than one race0000000
Unknown or Not Reported0000000
Region of Enrollment
Region of Enrollment(Participants)Treatment Sequence: ABCTreatment Sequence: BCATreatment Sequence: CABTreatment Sequence: ACBTreatment Sequence: CBATreatment Sequence: BACTotal
United States56555531
08

Study locations

2 sites
  • Covance Clinical Research Unit 1341 Mockingbird Lane
    Dallas, Texas 75247, United States
  • Covance Clinical Research Unit 3402 Kinsman Blvd
    Madison, Wisconsin 53704, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2020 to primary completion in Mar 2021, 3 months.

Results were first posted in Feb 2025, 3 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2023
First posted
Jan 22, 2024
StartActual
Dec 15, 2020
Primary completionActual
Mar 31, 2021
CompletionActual
Mar 31, 2021
Results first posted
Feb 24, 2025
Last update
Feb 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06215521
Collaborators
Loxo Oncology, Inc.
Responsible party
Sponsor
First posted
Jan 22, 2024
Start date
Dec 15, 2020
Primary completion
Mar 31, 2021
Completion
Mar 31, 2021
Results posted
Feb 24, 2025
Last update
Feb 24, 2025

Study contacts

Renee Ward, MD, PhD
study director · Loxo Oncology, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pirtobrutinib

Start the discussion